It can treat diabetes and obesity and reduce the risk of cardiovascular disease in patients with those conditions, so many were expecting Novo Nordisk A/S’s semaglutide to produce a further success in heart failure, and so it has proved. In a trial in obese patients with heart failure with preserved ejection fraction (HFpEF), the GLP-1 improved symptoms, physical limitations and exercise function compared with placebo – and also allowed greater weight loss.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?